 SBRT may be administered to 1-4 sites and the treatment sites can include prostate gland or prostate bed nodule for post-prostatectomy patients, bone metastases, and soft tissue metastases. Participants must have at least one site of disease that will be both irradiated with SBRT and biopsied to evaluate immunological outcomes. 